Alzheimer's and Parkinson's Disease


May 1, 2008
530 Pages - SKU: GJOB1874973
License type:
Table of Contents Related Reports
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Product Segments
Anti-Alzheimer’s Disease Drugs
Cholinesterase Inhibitors
NMDARA
Anti-Parkinson’s Disease Drugs
Dopaminergic Agents (Levodopa/Carbidopa)
Dopamine Agonists
Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine
Amplifiers)
COMT Inhibitors
MAO-B Inhibitors
Dopamine Amplifiers
II. EXECUTIVE SUMMARY
1. Outlook
Current and Future Analysis
2. Neurodegenerative Diseases Market - A Brief Overview
Key Brands in NDD Market
Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart)
Factors Affecting Market
Major Growth Drivers
Major Growth Inhibitors
Market Trends
High Prevalence Rates Drive Market Growth
Rapid Growth of Ageing Population
Price Hikes and Government Caps
Combination Therapy Gaining Ground
Research & Development
Future Holds Promise
3. Alzheimer’s Market Overview
A Peek at Anti-AD Drug Market
Impact of Dementia
Epidemiology
Table 2: World Alzheimer’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart)


Table 3: Alzheimer’s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ‘000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart)
Table 4: Alzheimer’s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart)
Patient Growth Drivers
Demographics Spell Opportunities
High Growth Rates for AD Drugs
The Impact of Aricept
Epic of NMDARA
Strengths
Weaknesses
Future Therapies
How Successful will the Late Stage Therapies be?
A Geographic Milieu
US
Europe
Japan
Alternative Drug Delivery Technologies Gaining Ground
Transdermal Patch
Domination of Acetyl Cholinesterase Inhibitors
Dramatic Changes in Market Lie Ahead
Advances in Next-Generation Treatments
Beta Amyloid Hypothesis
Growth Drivers
Ageing Baby Boomers Drive AD Market
Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart)
New Hypothesis Enables Effective Treatment
Unmet Medical Needs Drive Market Growth
Growth Inhibitors
Link with Other Aliments
Misdiagnosis
Patient Awareness
Medical Refunds
Competitive Landscape
Pharmaceutical Majors Rule the Market
Eisai/Pfizer
Novartis
Shire/Johnson & Johnson
Lundbeck/Forest
Ipsen and UCB
Table 6: Leading Brands in the Global Anti- Alzheimer’s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart)
Year of Approval of AD Drugs in Leading Countries
Compounds in Pipeline
Outlook for AD Drugs Market
4. Parkinson’s Disease Market Overview
An Alluring Market
Prevalence
Table 7: World Parkinson’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart)
Current Treatments
New Medicines on the Horizon
New Findings
Product Launches Through 2009
Dominance of Dopamine Agonists
Revival Revels in Other Anti-PD Drugs Segment
COMT Inhibitors Growing Fastest
Key Market Drivers
Rising Awareness Magnifies Patient Base
Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth
The Debut of Stalevo
Unmet Clinical Needs Show Mammoth Prospects
Key Market Inhibitors
Limitations of Existing Medicines Inhibit Market Growth
Under-Diagnosis Restrains Market Potential
Generic Competition from L-Dopa and Carbidopa Curbs Market Growth
Restricted Term of Dopamine Agonists Usage Delays Market Growth
5. Disease Overview
Alzheimer's Disease
Definition
The Cause
Finding AD
Prevention
Treatment
Parkinson’s Disease
Definition
Pathophysiology
Diagnosis
Prevalence
Treatment
Surgical Intervention
6. Drug Classification
Anti-Alzheimer’s’ Disease Drugs
NMDARA
Memantine
Cholinesterase Inhibitors (ChEIs)
Donepezil (Aricept)
Rivastigmine (Exelon)
Galantamine Hydrobromide (Razadyne)
Tacrine (Cognex)
Other Alternatives
Vitamin E
Estrogen Therapy
Anti-Inflammatory Drugs
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Antioxidants
Vaccine
Gingko Biloba
Pure Medical Nicotine
Anti-Parkinson’s Disease Drugs
Dopaminergic agents
Levodopa/Carbidopa
Dopamine Agonists
Pergolide/Permax
Bromocriptine/Parlodel
Ropinirole/Requip
Pramipexole/Mirapex
Cabergoline/Dostinex
Apomorphine/Apokyn
Other Dopamine Agonists
Other PD Drugs
COMT Inhibitors
Tolcapone (Tasmar)
Entacapone (Comtan)
MAO-B Inhibitors
Dopamine Amplifiers
Anticholinergics
7. Future Therapies
Alzheimer’s Disease
Key Pipeline Products
Phenserine
Ropern
Alzhemed
MEM 1003
Ampakine Compounds
Parkinson’s Disease
Key Pipeline Products
Adenosine A2a Antagonist
Spheramine®
Safinamide
O-1369
8. New Findings
Risedronate Minimizes Risk of Hip Fractures in PD Patients
Researchers Identify New Genes Responsible for AD
Researchers Establish a New Link Between Loneliness and AD
Researchers Try to Identify Early Stages of AD
SORL1 - The New Gene Found to be Responsible for AD
Scientists Conduct Research Work on CERE-120 Gene Therapy
Researchers Find New Snail Toxin for Nervous System Disorders
Researchers Study Anti-PD Properties of Nicotine
Researchers Establish New Link Between Pesticides and PD
Study Relates AD to the Quantity of Amyloid Protein
Researchers Establish Effectiveness of Gene Therapy on AD Patients
Scientists Use Electric Current to Treat PD Patients
Scientists Prove Earlier Assumptions Wrong
Scientists Discover 2 Distinct Types of MCIs
9. Recent Industry Activity
Eisai Acquires MGI Pharma
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Disease Treatment
Merz Licenses Anti-Alzheimer’s Drug Technology from TAU
Eisai Acquires Morphotek
Transition Therapeutics Acquires NeuroMedix
Evotec Teams Up with Boehringer Ingelheim
Siemens Signs Partnership Agreement with Wyeth
Digilab Receives Notice of Allowance for New Alzheimer's Biomarker
Pfizer Joins Forces with Genizon
Intellect Signs Licensing Agreement with IBL
Boehringer Ingelheim signs R&D agreement with Ablynx
Avicena Teams Up with NINDS for Phase III Trial of PD-02
Prana Begins Phase II clinical trial for PBT2
Idera Teams Up with Merck
Merck Signs R&D Agreement with Neuroptix
Neuro-Hitech Takes Over Q-RNA
Neurogen Inks Licensing Agreement with Wyeth
Acumen Revises License Agreement with Merck
Newron Begins 2nd Phase III clinical trial for Safinamide
Newron Inks Global Licensing Agreement with Serono
Pfizer Inks License Agreement with TransTech
CeNeS Renews R&D Agreement with Tripos
Athenagen Acquires Zapaq
Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591
Teva Receives Health Canada Clearance for Azilect
Valeant Introduces Zelapar Anti-PD Tablets in the US
Merck to Halt Further Development of Anti-PD Drug Called Sarizotan
Amarin Obtains Global Rights for New Apomorphine Formulation
FDA Clears Exelon for Parkinson's Disease
Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112
Pfizer Takes Over Rinat
TorreyPines Begins 2nd Phase-I clinical trial for NGX267
Kyowa Hakko Inks Licensing Agreement with Britannia
Schwarz Pharma Receives EMEA Clearance for Neupro
Evotec Inks Licensing Agreement with Roche
RheoGene Receives Funds from MJFF
Eisai Initiates Phase I clinical trial for E2012
Apokyn(R) Receives Approval in North America
FDA Approves Azilect
Voyager Completes Phase II Study for of Leuprolide Acetate
New Discovery for the Treatment of Alzheimer's Disease in Canada
Ortho-McNeil Launches Razadyne™ ER
Flurizan Enters Phase II Clinical Trials
Axonyx Releases Supplementary Results of Phase III Trial for Phenserine
Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist
BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinson's Animal
Models
Predix’s PRX-03140 Completes First Clinical Trial in Alzheimer's Disease
Galapagos and Senexis Expand Collaboration
Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch
Neurologix Posts Interim Results of Phase I Gene Therapy
GB Therapeutics Receives License for CHF1512
Alzhemed™ Begins Phase III Trials
Newron Commences Phase III Trial With Safinamide
Ceregene Bags FDA Approval for Gene Therapy Alzheimer's Study
Memantine Drug Receives Approval from FDA for Treatment of Alzheimer’s
FDA Grants Fast Track Designation
Ester Neurosciences Joins Forces with Pharmacopeia
10. Focus on Select Players
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb Co. (USA)
Eisai Inc. (USA)
Eli Lilly and Company (USA)
Forest Pharmaceuticals (USA)
GlaxoSmithKline PLC (UK)
H. Lundbeck A/S (Denmark)
Merz Pharmaceuticals GMBH (Germany)
Novartis AG (Switzerland)
Ortho-McNeil Neurologics, Inc. (USA)
Pfizer Inc (US)
Roche (Switzerland)
Shire Pharmaceuticals Group PLC (UK)
Valeant Pharmaceuticals International (USA)
11. Global Market Perspective
Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 9: World Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 10: World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)


Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 12: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 14: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 15: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 16: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012
Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)


Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart)


Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 22: World 9-Year Perspective for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart)


Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 24: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 26: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 27: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 28: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)


Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)


Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 36: World Long-term Projections for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
III. MARKET
1. The United States
A. Market Analysis
Current & Future Analysis
AD Market Overview
Approval of Cholinesterase Inhibitors for MCI to Drive Market
Competitive Landscape
Table 38: Leading Therapeutics in the North American Alzheimer’s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart)
Status of AD Drugs
New Products in Clinical Trails
Prevalence
Table 39: Alzheimer’s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart)
PD Therapies Market
Levodopa/Carbidopa on Declining Spree
Competition
Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart)
Patent Expiry Status
Patent Expiry Status of Parkinson’s Disease Drugs in the US
New Brands and Pipeline Analysis
PD Prevalence
New Findings
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 42: US Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 43: US 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2. Canada
A. Market Analysis
Current & Future Analysis
Prevalence
Strategic Corporate Developments
B. Market Analytics
Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 45: Canadian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 46: Canadian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3. Japan
A. Market Analysis
Current & Future Analysis
Prevalence
Strategic Corporate Developments
B. Market Analytics
Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 48: Japanese Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 49: Japanese 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4. Europe
A. Market Analysis
Current & Future Analysis
Prevalence
Alzheimer’s Disease
Table 50: European Alzheimer’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)
Parkinson’s Disease
Table 51: European Parkinson’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)
Competitive Scenario
Table 52: Leading Brands in the European Alzheimer’s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart)
Strategic Corporate Developments
B. Market Analytics
Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 54: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)


Table 56: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4a. Germany
A. Market Analysis
Current & Future Analysis
Prevalence
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 60: German Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 61: German 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4b. France
A. Market Analysis
Current & Future Analysis
Prevalence
B. Market Analytics
Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 63: French Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 64: French 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4c. United Kingdom
A. Market Analysis
Current & Future Analysis
Prevalence
New Findings
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 66: UK Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 67: UK 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4d. Italy
A. Market Analysis
Current & Future Analysis
Prevalence
Strategic Corporate Developments
B. Market Analytics
Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 69: Italian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugsby Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 70: Italian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4e. Spain
A. Market Analysis
Current & Future Analysis
Prevalence
B. Market Analytics
Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 72: Spanish Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 73: Spanish 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4f. Rest of Europe
A. Market Analysis
Current & Future Analysis
Prevalence
New Findings
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 76: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
5. Rest of World
A. Market Analysis
Current & Future Analysis
Prevalence
Strategic Corporate Developments
B. Market Analytics
Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 78: Rest of World Long-term Projections for Anti-Alzheimer’s & Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)


Table 79: Rest of World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 87 (including Divisions/Subsidiaries - 105)
Region/Country Players
The United States 51
Canada 5
Japan 3
Europe 36
France 1
Germany 9
The United Kingdom 11
Italy 2
Spain 3
Rest of Europe 10
Asia-Pacific (Excluding Japan) 5
Middle East 5
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Parkinson's Disease Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!